A1 adenosine-receptor antagonists activate chloride efflux from cystic fibrosis cells.

AUTOR(ES)

Eidelman, O

RESUMO

A1 adenosine-receptor-antagonist drugs such as 8-cyclopentyl-1,3-dipropylxanthine (CPX) and xanthine amine congener (XAC) are found to activate the efflux of 36Cl- from CFPAC cells. These cells are a pancreatic adenocarcinoma cell line derived from a cystic fibrosis (CF) patient homozygous for the common mutation, deletion of Phe-508. The active concentrations for these compounds are in the low nanomolar range, consistent with action on A1 adenosine receptors. In addition, drug action can be blocked by exogenous agonists such as 2-chloroadenosine and also can be antagonized by removal of endogenous agonists by treatment with adenosine deaminase. Cells lacking the CF genotype and phenotype, such as HT-29 and T84 colon carcinoma cell lines, appear to be resistant to activation of chloride efflux by either drug. CFPAC cells transfected with the CF transmembrane regulator gene, CFTR, are also resistant to activation by CPX. We conclude that, since these antagonists are of relatively low toxicity and appear to act somewhat selectively, they might be considered as promising therapeutic candidates for CF.

Documentos Relacionados

• GTP-binding proteins inhibit cAMP activation of chloride channels in cystic fibrosis airway epithelial cells.
• Chloride uptake into cultured airway epithelial cells from cystic fibrosis patients and normal individuals.
• A protective role for the A1 adenosine receptor in adenosine-dependent pulmonary injury
• The orphan receptor cDNA RDC7 encodes an A1 adenosine receptor.
• Transgenic A1 adenosine receptor overexpression increases myocardial resistance to ischemia